Fulgent Genetics Holds $330 Million To $340 Million Revenue Outlook As Billing Fix Drags On

Fulgent raised its cash forecast to about $630 million and cut its expected loss per share, while its billing overhaul remains unfinished.

Share
Fulgent Genetics Holds $330 Million To $340 Million Revenue Outlook As Billing Fix Drags On

Fulgent Genetics, a lab testing company that also develops cancer drugs, reaffirmed its $330 million to $340 million 2026 revenue outlook on its earnings call Thursday, while Chief Commercial Officer Brandon Perthuis said the company is "pretty deep into the game" on a billing-system overhaul that is still not finished.

A billing fix still being tuned

Fulgent is moving its billing and revenue cycle management to a new system. Perthuis said the company has cut into the required customizations and sees it in a better collection rate, but "We still have some fine-tuning to do."

Asked by a Piper Sandler analyst what inning the transition was in, Perthuis called the baseball framing "a little bit hard to say" before giving his answer. In prepared remarks he said management cannot predict more precise timing for improvements, though it has "a clear line of sight" to a return to historical collection rates.

CFO Paul Kim said gross margin improved faster than management expected and that there is "ample amount" of room to "continue to grind higher" with more work on collection policies.

Third-quarter numbers and the raised outlook

Third-quarter revenue was $90.4 million, up 8% from a year earlier and 6% from the second quarter, with $21.8 million from the BACO Diagnostics and StrataDx acquisitions. Anatomic pathology revenue rose 57% from a year earlier to $40.9 million, while precision diagnostics fell 18% to $41.8 million.

The adjusted operating margin was negative 13.2%, against negative 26.2% in the second quarter. Adjusted EBITDA was a loss of about $7.5 million, against a $17.1 million loss.

Kim said the full-year adjusted loss per share is now expected at $1.65 to $1.75, improved from $2.22 to $2.35. He forecast year-end cash near $630 million, up from $610 million. Cash stood at about $652.4 million at quarter end, helped by a $112.3 million federal tax refund.

Kim said the revenue range implies a fourth quarter roughly flat with the third at the midpoint, adding "we're not shooting for that." The top end leaves room for a sequential increase.

AI pathology and drug pipeline

Fulgent's AI platform analyzed about 255,000 slide images in the quarter, up 23% from the second quarter, and failed analyses fell to 0.01%. Perthuis said five more AI applications are planned for the fourth quarter.

On the drug side, CEO Ming Hsieh said FID-07 has finished most of its mid-stage trial and a late-stage study is in preparation. FID-022 is expected to reach its maximum tolerated dose determination in the first half of next year.

Fulgent plans to give its 2027 guidance when it reports fourth-quarter results, Kim said.

Sources